Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling

Avery Spitz

Rebecca Floyd

Jennifer Sutton

Linda Gardner

radioligand therapy, metastatic castration-resistant prostate cancer, [177Lu]Lu-PSMA-617
CJON 2023, 27(5), 539-547. DOI: 10.1188/23.CJON.539-547

Background: The approval of the prostate-specific membrane antigen (PSMA)–targeted radio-ligand therapy [177Lu]Lu-PSMA-617 represents a shift toward precision medicine–based treatments for metastatic castration-resistant prostate cancer.

Objectives: This review aims to provide practical advice and clinical considerations for working with [177Lu]Lu-PSMA-617; particularly, regarding the role of nurses in managing radiation safety, monitoring and reporting of adverse events, and counseling patients receiving this therapy.

Methods: Clinical data, protocols, and guidelines are summarized alongside real-world insights to provide practical recommendations for nurses caring for patients treated with [177Lu]Lu-PSMA-617.

Findings: Nurses coordinate safe care for patients receiving [177Lu]Lu-PSMA-617 by facilitating communication among physicians, managing logistic concerns, monitoring for adverse events related to treatment, providing education, and counseling patients and caregivers throughout treatment.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.